


| business Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis PR Newswire Asia |
|
Anti-ADAMTS5 Nanobody program is Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain. Merck receives upfront payment of € 50 million with the potential of receiving a further € 400 million related to delivering on certain development and commercial milestones.
Posted: 2020-10-06 15:06:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.